Barrington analyst Michael Petusky maintained a Buy rating on Landec Corp (LNDC) today and set a price target of $11.00. The company’s shares closed last Monday at $10.48.
According to TipRanks.com, Petusky is a 3-star analyst with an average return of 2.3% and a 48.2% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and Merit Medical Systems.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Landec Corp with a $14.00 average price target, representing a 30.2% upside. In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $17.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.57 and a one-year low of $9.02. Currently, Landec Corp has an average volume of 120.7K.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LNDC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Landec Corp. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Curation Foods, Lifecore, and Others. The Curation Foods segment includes activities to market and pack specialty packaged whole and fresh-cut fruit and vegetables.
